NCT07529613 2026-04-14
T-DXd_HER2Low
National Cancer Center Hospital East
Phase 1/2 Completed
Clinical Trials
91 trialsNCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT02205047 2025-07-31
INNOVATION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT04034251 2025-02-03
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT04281576 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NovoCure Ltd.
Phase NA Completed
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT04861987 2024-10-10
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
Processa Pharmaceuticals
Phase 1 Completed
NCT02746796 2024-05-03
Study of ONO-4538 in Gastric Cancer
Ono Pharmaceutical Co. Ltd
Phase 2/3 Completed
NCT03006705 2024-05-03
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Ono Pharmaceutical Co. Ltd
Phase 3 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT03607656 2023-12-18
CHANGE
Shanghai University of Traditional Chinese Medicine
Phase 2/3 Completed
NCT02555358 2023-10-19
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage â…¢ Clinical Study
Hebei Medical University
Phase 2 Completed
NCT02494583 2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT02335411 2022-08-08
KEYNOTE-059
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01711242 2022-05-05
Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
Wenzhou Medical University
Phase 2 Completed
NCT02395640 2021-10-26
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Phase 3 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT01774786 2020-12-30
JACOB
Hoffmann-La Roche
Phase 3 Completed
NCT02114359 2020-10-23
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
Seoul National University Hospital
Phase 3 Completed
NCT01516944 2020-02-13
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Hebei Medical University
Phase 2/3 Completed
NCT00446290 2020-01-18
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Asan Medical Center
Phase 1 Completed
NCT00565370 2020-01-18
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Asan Medical Center
Phase 1/2 Completed
NCT00398398 2020-01-07
Study of XELOX With Cetuximab in Advanced Gastric Cancer
Asan Medical Center
Phase 2 Completed
NCT01045538 2020-01-07
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP
Asan Medical Center
Phase 1/2 Completed
NCT01187212 2020-01-07
Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
Asan Medical Center
Phase 2 Completed
NCT01748773 2019-10-09
TOXAG
Hoffmann-La Roche
Phase 2 Completed
NCT00414271 2019-07-25
Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00003867 2018-09-10
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT01461057 2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2 Completed
NCT00938470 2018-03-29
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01843725 2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1 Completed
NCT02359058 2018-01-24
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01234324 2018-01-23
NEOPECX
AIO-Studien-gGmbH
Phase 2 Completed
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed